Biotech · Private company
Emerald Clinical Inc.
Track this companyFree. Adds Emerald Clinical Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials81 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- OST31-164Phase 2 · Bone CancerClinicalTrials.gov · fetched Nov 12, 2026
- pazopanibPhase 2 · ChondrosarcomaClinicalTrials.gov · fetched Nov 12, 2026
- pazopanibPhase 2 · OsteosarcomaClinicalTrials.gov · fetched Nov 12, 2026
- Dapagliflozin 10 MG [Farxiga]Diabetes Mellitus, Type 2ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Osteosarcoma Maintenance Therapy With OST31-164PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 21, 2021ClinicalTrials.gov NCT04974008 · fetched Nov 12, 2026
- Dapagliflozin Treatment in Type 2 DiabetesPHASE4 · COMPLETED · started Apr 20, 2021ClinicalTrials.gov NCT04620590 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney DiseasePHASE2 · TERMINATED · started Oct 1, 2020ClinicalTrials.gov NCT04492722 · fetched Nov 12, 2026
- Dapagliflozin in Respiratory Failure in Patients With COVID-19PHASE3 · COMPLETED · started Apr 22, 2020ClinicalTrials.gov NCT04350593 · fetched Nov 12, 2026
- Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis PatientsPHASE2 · TERMINATED · started Jun 1, 2019ClinicalTrials.gov NCT03821038 · fetched Nov 12, 2026
- A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast CancerPHASE3 · COMPLETED · started Mar 16, 2018ClinicalTrials.gov NCT03403712 · fetched Nov 12, 2026
- Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the LungPHASE2 · TERMINATED · started Apr 1, 2013ClinicalTrials.gov NCT01759303 · fetched Nov 12, 2026
- Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic ChondrosarcomaPHASE2 · COMPLETED · started Apr 1, 2011ClinicalTrials.gov NCT01330966 · fetched Nov 12, 2026